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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 



























• To understand the risks 
of COVID-19 and of 
vaccination to cerebral 
venous thrombosis 
(CVT) and portal vein 
thrombosis (PVT), 
electronic records were 
analysed from 59 
healthcare organisations 
in USA. 
• Included in the study 
was 513, 284 patients 
with a confirmed 
diagnosis of COVID-19 
(between Jan 202 and 
March 2021) and 20 
were diagnosed with 
CVT within 2 weeks 
following diagnosis (39 
per million people). 
From the 20 people with 
CVT, 4 patients died 
(20%). This was 
compared to 489, 
871  records of people 
receiving an mRNA-







vaccine where an CVT 
incidence of 4.1 per 
million was reported. 
• From the COVID-19 
confirmed group, 224 
had PVT (436 per 
million) which was 
compared to the post 
COVID-19 vaccine 
group were 22 cases of 
PVT were observed 
(44.9 per million), and 
post influenza vaccine 
group (98.4 per million). 
• EME monitoring system 
was used to compare to 
ChAdOx1 nCoV-19 
vaccine which reports 
CVT incidence of 5 per 
million. 
















• Brazil has experience 
high mortality due to 
COVID-19. The P1 
variant was identified in 
November 2020. The 
authors use genomic 
data, structure-based 
mapping of mutations 
of interest onto the 
spike protein, and 
dynamical 
epidemiology modelling 
of genomic and 
mortality data, to 
‘investigate the 
emergence of the P.1 
lineage and explore 
epidemiological 
explanations for the 
resurgence of COVID-
19 in Manaus’.  
• Using molecular clock 
phylogenetic, the 
authors estimate that 






around 15th Nov 2020 
‘and was preceded by a 
period of faster 
molecular evolution’. 
Using modelling, the 
authors report that P1 
is more transmissible 
than non-P1 linages in 
the Manus cohort (1.7-
2.4). They also 
estimate that an 
increase in mortality in 
the period following the 
emergence of P1 (1.2-
1.9), however other 
factors such as the 
pressure on the health 
system need to be 
considered and 
therefore the authors 
report that the cause of 
the relative mortality 
risk can therefore not 
be determined. The 
authors report that P.1 
linage ‘contains 10 
lineage-defining amino 
acid mutations in the 
virus spike protein 
(L18F, T20N, P26S, 
D138Y, R190S, K417T, 
E484K, N501Y, H655Y, 
T1027I) compared with 
its immediate ancestor 
(B.1.1.28)’. 
• In conclusion, the 
authors call for more 
sustainable genomic 
and epidemiological 
surveillance to identify 
and track variants of 
























• A rapid meta-
analysis was 












this included 14 
unpublished 
























































art of the 








































or death within 








felt over 28 
days. 





reduced time to 
recovery by a 
median of 3 
days. Of those 
that have 
contributed data 
for 28 days 










ongoing and has 



























can improve the 
knowledge, attitudes of 
young adults/youths in 
India. A large RCT with 
8376 participants  (15-
30 years) was 
conducted in urban 
India. Participants were 
randomly assigned to 
one of three cohorts: 1. 
Facts cohort where 
(10min) targeted fact 
based information via 
video was given 2. Fact 









contained the same 
facts with underlying 
scientific concepts 
(22min) or 3. Control 
group. a baseline 
survey on knowledge, 
attitudes and 
behaviours took place 
before the intervention. 
A survey was repeated 
following the 
intervention and then 
again one week later. 
• Both interventions 
improved knowledge 
with the ‘fact plus 
concepts’ group having 




• The authors conclude 
that communication for 
COVID-19 should take 
time to explain 
scientific concepts in 
order to improve 
knowledge, attitudes 
and behaviours of 
youths. 
14.04.2021 Examining 







• Case management 
costs for patients per 
day with COVID-19 
were estimated in 
Kenya. The authors 
reports that costs per 





COVID-19 treated at 
home, 1995.17 KES 
(US$18.991). For 
patients managed in an 





patients with severe 
COVID-19 disease 
managed in general 
Economic 
costs, Kenya 
hospital wards 13 
137.07 KES 
(US$124.53 and those 
with critical COVID-19 
disease admitted in 
intensive care units  63 
243.11 KES 
(US$599.51). The 
authors conclude that 
the cost of COVID-19 
per patient are 
substantial and 
therefore Kenya and 
other LMICs need to 




Comments, Editorials, Opinions, Blogs, News 
 Publication 
date 
Title/URL Journal | Article type 
19.04.2021 Human challenge trial launches to study immune 
response to COVID-19 
University of Oxford| 
News 
16.04.2021 Indoor Air Changes and Potential Implications for 
SARS-CoV-2 Transmission 
JAMA Network| JAMA 
Insights 
16.04.2021 Covid-19: Failed response in Brazil has led to 
humanitarian catastrophe, says MSF 
The BMJ| News 
16.04.2021 SARS-CoV-2 Vaccine–Induced Immune Thrombotic 
Thrombocytopenia 
The New England 
Journal of Medicine| 
Editorial 
16.04.2021 Triple jeopardy: disabled people and the COVID-19 
pandemic 
The Lancet| Comment 
15.04.2021 Risk of rare blood clotting higher for COVID-19 than 
for vaccines 
University of Oxford| 
News 
15.04.2021 Ten scientific reasons in support of airborne 
transmission of SARS-CoV-2 
The Lancet| Comment 
14.04.2021 Alternating vaccines trial expands to include two 
additional vaccines 
University of Oxford| 
News 
14.04.2021 Covid-19: How AstraZeneca lost the vaccine PR war  The BMJ Feature 
14.04.2021 Covid-19 has redefined airborne transmission The BMJ| Editorial 
14.04.2021 Covid-19: India authorises Sputnik V vaccine as 
cases soar to more than 180 000 a day 
The BMJ| News 
13.04.2021 Rethinking and strengthening the Global Health 
Diplomacy through triangulated nexus between policy 
makers, scientists and the community in light of 
COVID-19 global crisis 
Global Health Research 
and Policy| Perspective 
13.04.2021 Neglected tropical diseases as a barometer for 
progress in health systems in times of COVID-19 
BMJ Global Health| 
Commentary 
12.04.2021 Covid-19: Budesonide shortens recovery time in 
patients not admitted to hospital, study finds 
The BMJ| News 
12.04.2021 Asthma drug budesonide shortens recovery time in 
non-hospitalised patients with COVID-19 
Principle Trial| News 
 
  
Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 










• New cases have dramatically risen 
during India’s second wave in 
comparison to the first. The report 
acknowledges that whilst case fatality 
ratios are lower (1.3% to 0.87%), the 
number of infections is rising quicker, 
with a current average of 664 COVID-
related deaths per day, worst case 
predictions is that this could rise to 
2320 per day by June 2021 in the 
absence of efforts to mitigate this. 
COVID-19 has also disrupted routine 
health services and worsened the 
economy, therefore urgent action is 
recommended. Whilst many of these 
recommendations are within the 
Governments advisories and plans, the 
report recommend the following: 
o Vaccinations: Aggressive 
coverage of priority vaccination 
groups (45 years and above 
and those below 45 years with 
severe comorbidities); urgently 
approve and deploy a broader 
type of vaccines; increase 
manufacturing capacity for 
domestic use; address vaccine 
hesitancy; monitor collate and 
report on adverse events. 
o Non-pharmaceutical 
intervention: Re-launch public 
advocacy campaigns on mask 
wearing and safe behaviours; 
ban mass gatherings and large 
events (larger than 10 people 
for the next 2 months); 
community led, decentralised 
tracing, testing and isolating 
and community monitoring; 
scale up testing and record data 
on vaccination history and type 
on COVID-19 test registration 
forms. 
o Travel and mobility: recommend 
7 days mandatory quarantine 
for all international travellers; 
promote and support safe 
behaviours for domestic travel. 
o Teacher in schools and colleges 
should be vaccinated, and 
schools re-opened safely as 
advised in sister document. 
o Expand genome sequencing to 
better understand variants. 
o Strengthen the health system 
through: addressing bottlenecks 
in pharmaceutical supply chain 
to end shortage of essential 
medicines; invest in medical 
infrastructure; support 
workforce through training and 
psycho-social support. 
o Avoid national/state lockdown 
as this has significantly 
negatively impacted on the 
most marginalised, instead 
focus on local  level 
containment in consultation with 
local stakeholders. 
   
 
Dashboards & Trackers     












  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford Vaccine 
Trial 





US NIH   Our World in 
Data: C19 
Testing 





Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence      Our World in 
Data: COVID-
19 vaccinations  
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 




  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs    


















LSTM Stop TB 
Partnership 








  IDA 






















g in low 
resource 
settings 



























  Social 
Development 
Direct C19 blog 
series 






















Institute of Public 
Health 
    






Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     
UNESCO   medRxiv 
and bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 
  Science  Health systems 
Global 





  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  













      
WorldPop           
Flowminder           





    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
15.04.2021 How can evaluation 
work support greater 
vaccine equity for 
COVID-19? 
Webinar 1h Itad 
12.04.2021 COVID-19: Vaccines 
Safety Webinar - 
Understanding the Facts 
& Myths 
Webinar 1.5h Asia Pacific 
Association of 
Allergy, Asthma and 
Clinical Immunology 
07.04.2021 Public webinar 'The 
RECOVERY Trial: one 
year on' 
Webinar 1h Nuffield Department 
of Population Health 
25 March 
2021 
UK Public Health Rapid 
Support Team: Latest 
research & scientific 
insights 
Webinar 1h LSHTM 
18 March 
2021 
Africa taking charge of 
its future: prioritizing 
gender equality in the 
path to recovery 
Webinar 1h 30 CGD 
10 March 
2021 
Equity and scale in 
global immunization: 
new evidence from 
Nigeria on cash 
transfers for vaccination 
Webinar 1h 15 CGD 
9 March 
2021 
COVID-19 vaccines and 
Africa: where do we 









Diseases in the COVID 
era 




training for health 
workers 
Online training 3h  WHO 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during the 
COVID-19 pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply chain 
resilience and global 
trade 
Webinar 1h CGD 
03.12.2020 More money for health 
services: What is the 
tole of PFM in the “new 
normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental wellbeing 
of community health 
workers on the COVID-
19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the pandemic 
with a gender lens 
Live Twitter 
conversation 
  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to promote 
sharing of experience 
and expertise around 
the maintenance of 
essential health services 




starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the Economic 
and Health Impact of 
COVID-19 across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
Online courses Varies WHO 
emergencies, now offers 
10 online courses 










Nursing in Times of 
Crisis 






School of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 




Modelling and Policy 
Online learning 2 weeks 








11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 




Virtual Evidence Weeks 5 sessions 1h 30 International Initiative 











COVID-19 Open online 
brief with Dr David 
Nabarro 





Online learning 3 hours WHO 
COVID-19: methods for 
detection, prevention, 




19: Real-time training 
for the coronavirus 
disease outbreak 







COVID-19: Tackling the 
Novel Coronavirus 
Online learning 3 weeks 
















Online learning 3 weeks 







COVID-19 Critical Care: 
Understanding and 
Application 
Online learning 5 weeks 





Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary 
research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease 
control and health system responses are included. Articles related to tackling the secondary impacts on other 
sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected based on 
relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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